Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 7Adenoma, Islet Cell 2Uveal Melanoma 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma 1Non functioning pancreatic endocrine tumor 1Neoplasm Metastasis 1Multiple Sclerosis 1Metastatic Digestive System Neuroendocrine Tumor G1 1Melanoma 1Breast Neoplasms 1Brain Neoplasms 1Advanced Lung Neuroendocrine Tumor 1Adrenocortical Carcinoma 1Adenocarcinoma of Lung 1

Interventions

lutetium Lu 177 dotatate 1X-Rays 1Specimen Handling 1Photons 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Lung Neuroendocrine Tumor × Specimen Handling × NET × Clear all
NCT04665739 2026-05-13

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
70 enrolled
EndocrineNET

Advanced Lung Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡